N/A
Manufactured by ANI Pharmaceuticals, Inc.
9,944 FDA adverse event reports analyzed
Last updated: 2026-04-15
ACETAZOLAMIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ANI Pharmaceuticals, Inc.. The most commonly reported adverse reactions for ACETAZOLAMIDE include OFF LABEL USE, DRUG INEFFECTIVE, HEADACHE, CONDITION AGGRAVATED, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ACETAZOLAMIDE.
Out of 5,628 classified reports for ACETAZOLAMIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 9,944 FDA FAERS reports that mention ACETAZOLAMIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, HEADACHE, CONDITION AGGRAVATED, FATIGUE, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list ANI Pharmaceuticals, Inc. in connection with ACETAZOLAMIDE. Always verify the specific product and NDC with your pharmacist.